{
  "address1": "One Amgen Center Drive",
  "city": "Thousand Oaks",
  "state": "CA",
  "zip": "91320-1799",
  "country": "United States",
  "phone": "805 447 1000",
  "fax": "805 447 1010",
  "website": "https://www.amgen.com",
  "industry": "Drug Manufacturers\u2014General",
  "industryDisp": "Drug Manufacturers\u2014General",
  "sector": "Healthcare",
  "sectorDisp": "Healthcare",
  "longBusinessSummary": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh\u00e7et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.",
  "fullTimeEmployees": 25200,
  "companyOfficers": [
    {
      "maxAge": 1,
      "name": "Mr. Robert A. Bradway",
      "age": 59,
      "title": "Chairman, CEO & Pres",
      "yearBorn": 1963,
      "fiscalYear": 2022,
      "totalPay": 5487475,
      "exercisedValue": 0,
      "unexercisedValue": 43693576
    },
    {
      "maxAge": 1,
      "name": "Mr. Peter H. Griffith",
      "age": 63,
      "title": "Exec. VP & CFO",
      "yearBorn": 1959,
      "fiscalYear": 2022,
      "totalPay": 2574004,
      "exercisedValue": 0,
      "unexercisedValue": 245771
    },
    {
      "maxAge": 1,
      "name": "Mr. Esteban  Santos",
      "age": 54,
      "title": "Exec. VP of Operations",
      "yearBorn": 1968,
      "fiscalYear": 2022,
      "totalPay": 2521941,
      "exercisedValue": 0,
      "unexercisedValue": 8232750
    },
    {
      "maxAge": 1,
      "name": "Dr. David M. Reese M.D.",
      "age": 59,
      "title": "Exec. VP of R&D",
      "yearBorn": 1963,
      "fiscalYear": 2022,
      "totalPay": 2833393,
      "exercisedValue": 0,
      "unexercisedValue": 4932458
    },
    {
      "maxAge": 1,
      "name": "Mr. Murdo  Gordon",
      "age": 55,
      "title": "Exec. VP of Global Commercial Operations",
      "yearBorn": 1967,
      "fiscalYear": 2022,
      "totalPay": 2717562,
      "exercisedValue": 0,
      "unexercisedValue": 2469817
    },
    {
      "maxAge": 1,
      "name": "Mr. Matthew C. Busch",
      "age": 48,
      "title": "Chief Accounting Officer & VP of Fin.",
      "yearBorn": 1974,
      "exercisedValue": 0,
      "unexercisedValue": 0
    },
    {
      "maxAge": 1,
      "name": "Mr. Mike  Zahigian",
      "title": "Sr. VP & Chief Information Officer",
      "exercisedValue": 0,
      "unexercisedValue": 0
    },
    {
      "maxAge": 1,
      "name": "Mr. Arvind  Sood",
      "title": "VP of Investor Relations",
      "exercisedValue": 0,
      "unexercisedValue": 0
    },
    {
      "maxAge": 1,
      "name": "Mr. Jonathan P. Graham",
      "age": 61,
      "title": "Exec. VP, Gen. Counsel & Sec.",
      "yearBorn": 1961,
      "fiscalYear": 2019,
      "exercisedValue": 0,
      "unexercisedValue": 0
    },
    {
      "maxAge": 1,
      "name": "Ms. Nancy A. Grygiel",
      "age": 54,
      "title": "Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer",
      "yearBorn": 1968,
      "exercisedValue": 0,
      "unexercisedValue": 0
    }
  ],
  "auditRisk": 4,
  "boardRisk": 9,
  "compensationRisk": 3,
  "shareHolderRightsRisk": 1,
  "overallRisk": 3,
  "governanceEpochDate": 1693526400,
  "compensationAsOfEpochDate": 1672444800,
  "maxAge": 86400,
  "priceHint": 2,
  "previousClose": 269.41,
  "open": 267.67,
  "dayLow": 266.56,
  "dayHigh": 269.495,
  "regularMarketPreviousClose": 269.41,
  "regularMarketOpen": 267.67,
  "regularMarketDayLow": 266.56,
  "regularMarketDayHigh": 269.495,
  "dividendRate": 8.52,
  "dividendYield": 0.031600002,
  "exDividendDate": 1692230400,
  "payoutRatio": 0.5485,
  "fiveYearAvgDividendYield": 2.93,
  "beta": 0.613762,
  "trailingPE": 18.039083,
  "forwardPE": 15.005606,
  "volume": 1696497,
  "regularMarketVolume": 1696497,
  "averageVolume": 2504120,
  "averageVolume10days": 2688510,
  "averageDailyVolume10Day": 2688510,
  "bid": 267.41,
  "ask": 267.76,
  "bidSize": 900,
  "askSize": 1000,
  "marketCap": 143192997888,
  "fiftyTwoWeekLow": 211.71,
  "fiftyTwoWeekHigh": 296.67,
  "priceToSalesTrailing12Months": 5.386841,
  "fiftyDayAverage": 250.8634,
  "twoHundredDayAverage": 244.32005,
  "trailingAnnualDividendRate": 8.14,
  "trailingAnnualDividendYield": 0.030214172,
  "currency": "USD",
  "enterpriseValue": 171403722752,
  "profitMargins": 0.30017,
  "floatShares": 533756492,
  "sharesOutstanding": 534900992,
  "sharesShort": 6199626,
  "sharesShortPriorMonth": 6511830,
  "sharesShortPreviousMonthDate": 1690761600,
  "dateShortInterest": 1693440000,
  "sharesPercentSharesOut": 0.0116,
  "heldPercentInsiders": 0.0023700001,
  "heldPercentInstitutions": 0.79324996,
  "shortRatio": 2.49,
  "shortPercentOfFloat": 0.0116,
  "impliedSharesOutstanding": 534900992,
  "bookValue": 12.677,
  "priceToBook": 21.116985,
  "lastFiscalYearEnd": 1672444800,
  "nextFiscalYearEnd": 1703980800,
  "mostRecentQuarter": 1688083200,
  "earningsQuarterlyGrowth": 0.047,
  "netIncomeToCommon": 7978999808,
  "trailingEps": 14.84,
  "forwardEps": 17.84,
  "pegRatio": 9.86,
  "lastSplitFactor": "2:1",
  "lastSplitDate": 943228800,
  "enterpriseToRevenue": 6.448,
  "enterpriseToEbitda": 12.454,
  "52WeekChange": 0.18750823,
  "SandP52WeekChange": 0.18466556,
  "lastDividendValue": 2.13,
  "lastDividendDate": 1692230400,
  "exchange": "NMS",
  "quoteType": "EQUITY",
  "symbol": "AMGN",
  "underlyingSymbol": "AMGN",
  "shortName": "Amgen Inc.",
  "longName": "Amgen Inc.",
  "firstTradeDateEpochUtc": 424704600,
  "timeZoneFullName": "America/New_York",
  "timeZoneShortName": "EDT",
  "uuid": "9376b97e-b428-3231-ba0b-142b20481cb4",
  "messageBoardId": "finmb_24816",
  "gmtOffSetMilliseconds": -14400000,
  "currentPrice": 267.7,
  "targetHighPrice": 300.38,
  "targetLowPrice": 173.66,
  "targetMeanPrice": 247.52,
  "targetMedianPrice": 248.75,
  "recommendationMean": 2.5,
  "recommendationKey": "buy",
  "numberOfAnalystOpinions": 19,
  "totalCash": 34247999488,
  "totalCashPerShare": 64.027,
  "ebitda": 13763000320,
  "totalDebt": 61544001536,
  "quickRatio": 2.344,
  "currentRatio": 2.771,
  "totalRevenue": 26581999616,
  "debtToEquity": 907.595,
  "revenuePerShare": 49.732,
  "returnOnAssets": 0.08541001,
  "returnOnEquity": 1.73457,
  "grossProfits": 19917000000,
  "freeCashflow": 10054124544,
  "operatingCashflow": 10800000000,
  "earningsGrowth": 0.049,
  "revenueGrowth": 0.059,
  "grossMargins": 0.74294996,
  "ebitdaMargins": 0.51776004,
  "operatingMargins": 0.38443002,
  "financialCurrency": "USD",
  "trailingPegRatio": 1.9849
}